Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles
Paul Goepfert(University of Maryland, Baltimore), Harriet L. Robinson(GeoVax (United States)), Linda S. Wyatt(National Institute of Allergy and Infectious Diseases), Olivier Defawe(Infectious Disease Research Institute), Georgia D. Tomaras(National Institutes of Health), Bernard Moss(National Institute of Allergy and Infectious Diseases), M. Cardinali(National Institute of Allergy and Infectious Diseases), Spyros A. Kalams(Vanderbilt University Medical Center), Alicia Sato, Sharon E. Frey(St. Louis VA Medical Center), Lilin Lai(Emory Healthcare), Lindsey R. Baden(Brigham and Women's Hospital), Qin Li(Fujian Normal University), Yongxian Xu(GeoVax (United States)), John Hural(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Christine M. Hay(University of Rochester), William A. Blattner(Unknown), David C. Montefiori(Duke University), Stephen C. DeRosa(Infectious Disease Research Institute), Marnie Elizaga(Fred Hutch Cancer Center)
Cited by 177
Related Papers
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
|Cell|2020|4.5k
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k